$ARNA Headlines S&P 500 back for another crack at major

New Post Public Reply Private Reply Replies (0) Message Board

Dec 27, 2014 at 10:03 AM

$ARNA Headlines

S&P 500 back for another crack at major support 11:21 a.m. Jan. 31, 2014 - Michael Ashbaugh
Arena shares surge as marketer doubles sales force for diet drug 11:41 a.m. Oct. 15, 2013 - Russ Britt
Obesity drug makers jockey for position as analysts praise Vivus 12:06 p.m. Oct. 3, 2013 - Russ Britt
Hedge funds are buying these stocks right now 1:46 p.m. July 23, 2013 - Insider Monkey
5 stocks insiders are buying 1:52 p.m. June 7, 2013 - Insider Monkey
6 gut checks before the stock market's opening bell 6:47 a.m. March 7, 2013 - Shawn Langlois
Stocks to watch Monday: Transocean, Stratasys 9:22 a.m. March 4, 2013 - Sue Chang
Arena Pharmaceuticals down 7.4% in premarket 9:11 a.m. Jan. 22, 2013 - Steve Gelsi
What 2012’s winners and losers say about 2013 6:00 a.m. Dec. 14, 2012 - Howard Gold
6 gut checks before the stock market's opening bell 6:50 a.m. Dec. 12, 2012 - Shawn Langlois
4 charts challenging resistance 7:06 a.m. Oct. 16, 2012 - The Trading Deck
Vivus sees EU regulators rejecting diet drug 12:16 p.m. Sept. 21, 2012 - MarketWatch.com
Vivus falls 11% on EU drug approval update 11:07 a.m. Sept. 21, 2012 - Val Brickates Kennedy
Arena rises as Vivus sees anti-obesity setback 7:49 a.m. Sept. 21, 2012 - Greg Morcroft
Vivus says Europe likely to reject obesity drug 7:33 a.m. Sept. 21, 2012 - MarketWatch.com
Orexigen soars 19% on analyst buy rating 12:46 p.m. Sept. 6, 2012 - Val Brickates Kennedy
Arena jumps 12% amid takeover speculation 1:55 p.m. Aug. 14, 2012 - Val Brickates Kennedy
Arena trips Nasdaq short-sale circuit breaker 3:01 p.m. Aug. 1, 2012 - Val Brickates Kennedy
Arena Pharma share drop trips short-sale limit 2:16 p.m. Aug. 1, 2012 - Laura Mandaro
Eisai gears up for launch of Arena's diet drug 9:32 a.m. July 30, 2012 - Val Brickates Kennedy

Is Vivus Headed Towards An Unfortunate Ending? 8:27 a.m. Today - Seeking Alpha
4 Potential Blockbuster Drugs The FDA Just Approved 11:35 a.m. Dec. 26, 2014 - Investors Business Daily
First Week Of March 2015 Options Trading For Arena Pharmaceuticals 11:32 a.m. Dec. 26, 2014 - TheStreet.com
Arena Pharmaceuticals (ARNA): Today's Weak On High Volume Stock 10:22 a.m. Dec. 26, 2014 - TheStreet.com
Novo Nordisk's Saxenda Gets FDA Nod, Launch in 1H15 - Analyst Blog 4:20 p.m. Dec. 24, 2014 - Zacks.com
Novo Nordisk Enters Anti-Obesity Space With New FDA Approval 7:46 a.m. Dec. 24, 2014 - Seeking Alpha
FDA clears Novo weight management drug 4:05 p.m. Dec. 23, 2014 - Seeking Alpha
Contrave Prescriptions Still Rising In A Down Week 3:47 p.m. Dec. 22, 2014 - Seeking Alpha
Orexigen - Contrave Script Numbers Remain Impressive 3:31 p.m. Dec. 22, 2014 - Seeking Alpha
Belviq Scripts Dip - Lack Of T.V. Ads Will Impact Next Numbers 3:27 p.m. Dec. 22, 2014 - Seeking Alpha
Orexigen Retreats After Positive News In Europe: 3 Things To Watch For 3:18 p.m. Dec. 22, 2014 - Seeking Alpha
Arena And Vivus Investors Need To Grasp Implications Of Orexigen 2:22 p.m. Dec. 19, 2014 - Seeking Alpha
Orexigen Therapeutics Gains On Diet Pill Nod From European Committee 1:09 p.m. Dec. 19, 2014 - benzinga.com
Orexigen's 'Goldilocks' Weight-Loss Pill is Just Right for European Regulators 8:25 a.m. Dec. 19, 2014 - TheStreet.com
Low-Cost Contrave Fuels Anti-Obesity Drugs Recovery From Thanksgiving 1:50 a.m. Dec. 16, 2014 - Seeking Alpha
Why Should Investors Expect Physicians To Treat Obesity With Pharmacotherapy? 10:30 a.m. Dec. 15, 2014 - Seeking Alpha
Zafgen starts clinical trial in severe obesity and type 2 diabetes 7:43 a.m. Dec. 15, 2014 - Seeking Alpha
Contrave Sales Continue To Impress 4:26 p.m. Dec. 12, 2014 - Seeking Alpha
Arena: Belviq Sales See Pleasant Rebound 4:05 p.m. Dec. 12, 2014 - Seeking Alpha
Arena Pharmaceuticals (ARNA) Weak On High Volume Today 10:01 a.m. Dec. 12, 2014 - TheStreet.com

Arena Pharmaceuticals Issued Composition of Matter Patent by United States Patent and Trademark Office for Ralinepag and Related Compounds 8:00 a.m. Nov. 25, 2014 - PR Newswire - PRF
Arena Pharmaceuticals to Present at Piper Jaffray 26th Annual Healthcare Conference 8:00 a.m. Nov. 24, 2014 - PR Newswire - PRF
Technical Updates on Biotech Stocks - ImmunoGen, Lexicon Pharma, ZIOPHARM Oncology, Arena Pharma, and Regulus Therapeutics 8:40 a.m. Nov. 19, 2014 - PR Newswire - PRF
Arena Pharmaceuticals to Present at Stifel 2014 Healthcare Conference 8:00 a.m. Nov. 13, 2014 - PR Newswire - PRF
Lorcaserin HCl Data to be Presented at the Annual Meeting of the American Association for the Study of Liver Diseases 8:00 a.m. Nov. 6, 2014 - PR Newswire - PRF
Arena Pharmaceuticals to Present at Credit Suisse 2014 Healthcare Conference 8:00 a.m. Nov. 5, 2014 - PR Newswire - PRF
Arena Pharmaceuticals Provides Corporate Update and Reports Third Quarter 2014 Financial Results 6:45 a.m. Nov. 3, 2014 - PR Newswire - PRF
Eisai and Arena Pharmaceuticals Report Results of an Investigational Phase 2 Trial of Lorcaserin HCl as an Aid for Smoking Cessation 6:30 a.m. Nov. 3, 2014 - PR Newswire - PRF
Lorcaserin Data to be Presented at The Obesity Society's Annual Scientific Meeting 7:37 a.m. Oct. 31, 2014 - PR Newswire - PRF
Lorcaserin Data to be Presented at The Obesity Society's Annual Scientific Meeting 7:00 a.m. Oct. 31, 2014 - PR Newswire - PRF
Eisai and Arena Pharmaceuticals Report Results of an Investigational Pilot Study of Coadministration of Lorcaserin HCl and Phentermine HCl 5:20 p.m. Oct. 28, 2014 - PR Newswire - PRF
Arena Pharmaceuticals Announces Third Quarter 2014 Conference Call and Webcast on Monday, November 3 7:00 a.m. Oct. 27, 2014 - PR Newswire - PRF
Biotech Equities Technical Briefing - Arena Pharma, NPS Pharma, XOMA, Momenta Pharma, and Catalyst Pharma Partners 8:30 a.m. Oct. 17, 2014 - PR Newswire - PRF
Global Anti-Obesity Drugs Market 4:07 p.m. Oct. 16, 2014 - PR Newswire - PRF
Eisai and Arena Pharmaceuticals Announce Publication of Pooled Phase 3 Clinical Trial Analysis of BELVIQ® (lorcaserin HCl) CIV in Postgraduate Medicine 10:36 a.m. Oct. 10, 2014 - PR Newswire - PRF
Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference 7:00 a.m. Sept. 22, 2014 - PR Newswire - PRF
Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 7:15 a.m. Sept. 19, 2014 - PR Newswire - PRF
Technical Coverage on Biotech Stocks - Exelixis, Arena Pharma, Novavax, Dendreon, and Amicus Therapeutics 7:40 a.m. Sept. 12, 2014 - PR Newswire - PRF
Arena Pharmaceuticals' APD811 Granted Orphan Drug Status for Pulmonary Arterial Hypertension 7:00 a.m. Sept. 2, 2014 - PR Newswire - PRF
Post-Earnings Review and Highlights - Arena Pharma 8:30 a.m. Aug. 11, 2014 - PR Newswire - PRF

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Baidu's Stock Connect Inclusion: What It Means for Investors

An Intriguing Move For Baidu's Class A Shares Well, here we go again, folks. Another move on the chessboard for Baidu. They've just walked their Class A ordinary shares onto the Shenzhen-Hong Kong and Shanghai-Hong Kong Stock Connects. As of today, September 7, 2026, mainland investors can now get their mitts on these shares more easily. It might not be a...

WEPSEA 2026 Propels Southeast Asia's Packaging Leap

Revolution in Packaging: Southeast Asia Steps Up Get ready for a wake-up call in the world of packaging, folks; the Southeast Asian market is taking a sharp turn toward sustainability and technological advancement, as highlighted by WEPSEA 2026's recent wrap-up in Shanghai. Far from a mere exhibition, this gathering served as the crucible for change, where old-school...

DUVA ONE Sleep Earbuds: Real-Time Innovation Debuts

While You Dream, DUVA ONE Works Here's the scoop: DUVA just took sleep tech to another level with their DUVA ONE earbuds launched at Berlin's IFA 2026. These aren't just any earbuds; they're engineered to actually do something while you're sleeping. DUVA ONE senses what’s happening during your snooze session and adjusts right on the fly. The Night Patrol: In-Ear and...

Clover's RSV Combo Vaccine Shows Promise in Trials

In the biotech world, there's always a race. Clover Biopharmaceuticals is making strides with their RSV+hMPV vaccine candidate, especially for the elderly. Imagine those big leaps in development—all boosted by recent results from a Phase 2 trial down under in Australia. Key Findings of the Trial Immunogenicity Insights They're not messing around with these findings. The...

Changhong's IFA 2026 Showcase: AI, Culture & Localization

Changhong's Game Plan: From Global Reach to Local Touch Well, Changhong's not sitting back at IFA 2026, let me tell you that. This isn't your run-of-the-mill showcase; it's a full-on reveal of what happens when a company takes AI tech and tunes it to the heartbeat of daily life. TVs, fridges, air conditioners—you name it, they've got an AI twist on it. But is this just...

Harbour BioMed Joins Stock Connect, Boosts Investor Access

The Big Leap: Harbour BioMed Joins Stock Connect Well, if this ain't something to get excited about—Harbour BioMed just snagged a spot on the Stock Connect roster. This step isn't just ceremonial. We're talking about real access for mainland Chinese investors to dive directly into the shares of Harbour BioMed (HKEX: 02142.HK) through the Shanghai-Hong Kong and...

MERACH Unveils W60 Plus: A Game Changer for Home Fitness

MERACH's Ambitious Leap into European Markets Walking is one of life's simple pleasures, but it's not always convenient in our work-from-home driven world. That's where MERACH's UltraWalk W60 Plus comes in, dropping anchor in Europe like a brand new ship with all the bells and whistles. What makes this walking pad different, you ask? It's designed to become a natural...

Mermaid Folklore Meets Revolution in New Short Film

A Sea Haunting Like No Other Ever feel like history's forgotten tales deserve a fresh spin? Well, this one's shaking it up! Hoyt Dwyer, an Atlanta filmmaker, flips the script on a lesser-known bit from the American Revolution. Yeah, we're talking about Hessian soldiers and sirens here. Just hang on to your hats because this ain't your typical historical retelling. A...

Aroa Biosurgery Reports Low Infection Rates: A Milestone

Peer-Reviewed Study: Aroa's Myriad Shows Low Infection Rates Seems like the folks at Aroa Biosurgery have got something solid to brag about in the world of complex soft tissue reconstruction. The company just released interim results from their massive MASTRR Registry study, and the numbers are looking pretty darn promising. We're talking about a 411-patient analysis...

Softcare Facilitates Standards Delegation Visit to Senegal

Ever seen a whole nation's hygiene industry getting a deep dive from not just one, but three major standards bodies? That's what just went down in Senegal. Softcare opened its doors wide to folks from the Senegalese Association for Standardization (ASN), the International Organization for Standardization (ISO), and the Swedish Institute for Standards (SIS). This was no...